ALNOV:EPA
Novacyt SA
0,44 €
0,00%
(0,00) 1 p
19. nov, 12:17:13 GMT +1 · EUR
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse ALNOV põhistatistika genereerimine…
Ava
0,44 €
Kõrge
0,44 €
Madal
0,44 €
Turu kapit.
32,30 mln
Keskm. maht
136,90 tuh
Maht
45,07 tuh
52 näd kõrgeim
1,04 €
52 näd madalaim
0,29 €
Aktsiatulu
−0,38 €
Käibivad aktsiad
72,59 mln
Töötajate arv
228
Ava
0,44 €
Kõrge
0,44 €
Madal
0,44 €
Turu kapit.
32,30 mln
Keskm. maht
136,90 tuh
Maht
45,07 tuh
52 näd kõrgeim
1,04 €
52 näd madalaim
0,29 €
Aktsiatulu
−0,38 €
Käibivad aktsiad
72,59 mln
Töötajate arv
228
Uudised
Veebiallikatest ja uudistepartneritelt
Barron's
·
33 minuti eest
Sell the S&P 500 Because the AI Bubble Is About to Burst, Analyst Says. Buy This Instead.
Yahoo Finance
·
1 tunni eest
Is Investing in an S&P 500 ETF Really Enough? Here's My Honest Take.
Traders Union
·
9 tunni eest
S&P 500 lange tõusu järel alla 200 päeva libiseva keskmise, märgib Ryan Detrick
Los Angeles Times
·
14 tunni eest
A fifth straight drop for the S&P 500 drags Wall Street to its longest losing streak since June
Profiil
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Teave üksuse Novacyt SA kohta
TegevjuhtDavid Allmond
Töötajad228
Asutatud3. juuli 2006
Peakontorid-
SektorHealth Care
Valdkond-
Veebisaitnovacyt.com